UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 2341-2
Program Prior Authorization/Medical Necessity
Medication *Spevigo® (spesolimab-sbzo) injection
*This program applies to the subcutaneous formulations of Spevigo
P&T Approval Date 5/2024, 5/2025
Effective Date 7/1/2025
1. Background:
Spevigo is an interleukin-36 receptor antagonist indicated for the treatment of generalized
pustular psoriasis (GPP) in adults and pediatric patients 12 years of age and older and weighing
at least 40 kg.
2. Coverage Criteriaa:
A. Initial Authorization
1. Spevigo will be approved based on all of the following criteria:
a. Diagnosis of generalized pustular psoriasis (GPP) based on both of the following:
(1) Presence of primary, sterile, macroscopically visible pustules on erythematous
base
(2) Pustulation is not restricted to the acral region or within psoriatic plaques
-AND-
b. Both of the following:
(1) Used to prevent GPP flares
(2) Patient is not currently experiencing a GPP flare
-AND-
c. One of the following:
(1) Patient has been established on therapy with Spevigo for GPP under an active
UnitedHealthcare medical benefit prior authorization
-OR-
(2) Both of the following:
(a) Patient is currently on Spevigo therapy for GPP as documented by claims
history or submission of medical records (Document date and duration of
therapy)
-AND-
© 2025 UnitedHealthcare Services, Inc.
1
(b) Patient has not received a manufacturer supplied sample at no cost in the
prescriber’s office, or via manufacturer’s patient assistance programs (e.g.,
sample card which can be redeemed at a pharmacy for a free supply of
medication) as a means to establish as a current user of Spevigo*
-AND-
d. Patient is not receiving Spevigo in combination with another targeted
immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi
(golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant
(baricitinib), Rinvoq (upadacitinib), ustekinumab, Skyrizi (risankizumab)] for
treatment of the same indication
-AND-
e. Prescribed by a dermatologist
* Patients requesting initial authorization who were established on therapy via the receipt of a
manufacturer supplied sample at no cost in the prescriber’s office or via manufacturer’s patient
assistance programs shall be required to meet initial authorization criteria as if patient were new
to therapy.
Authorization will be issued for 12 months.
B. Reauthorization
1. Spevigo will be approved based on all of the following criteria:
a. Documentation of positive clinical response to therapy [e.g., preventing flares,
reducing frequency of flares, prolonging time between flares, controlling signs and
symptoms of GPP (e.g. pustules, erythema, pain, itching) between flares]
-AND-
b. Reduction in the utilization of therapy (e.g., intravenous Spevigo) used for GPP
flares
-AND-
c. Patient is not receiving Spevigo in combination with another targeted
immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi
(golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant
(baricitinib), Rinvoq (upadacitinib), ustekinumab, Skyrizi (risankizumab)] for
treatment of the same indication
-AND-
d. Prescribed by a dermatologist
© 2025 UnitedHealthcare Services, Inc.
2
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limits may be in place.
4. References:
1. Spevigo [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; March
2024.
2. Bachelez H, Choon SE, Marrakchi S, et al. Trial of Spesolimab-sbzo for Generalized Pustular
Psoriasis. N Engl J Med. 2021;385(26):2431-2440. doi:10.1056/NEJMoa2111563.
3. Navarini AA, Burden AD, Capon F, et al. European consensus statement on phenotypes of
pustular psoriasis. J Eur Acad Dermatol Venereol. 2017;31(11):1792-1799.
doi:10.1111/jdv.14386.
4. Armstrong AW, Elston CA, Elewski BE, et al. Generalized pustular psoriasis: A consensus
statement from the National Psoriasis Foundation. J Am Acad Dermatol. 2024;90(4):727-730.
doi:10.1016/j.jaad.2023.09.080
5. Choon SE, van de Kerkhof P, Gudjonsson JE, et al. International Consensus Definition and
Diagnostic Criteria for Generalized Pustular Psoriasis From the International Psoriasis
Council. JAMA Dermatol. 2024;160(7):758-768. doi:10.1001/jamadermatol.2024.0915
6. Barker JN, Casanova E, Choon SE, et al. Global Delphi consensus on treatment goals for
generalized pustular psoriasis. Br J Dermatol. 2025;192(4):706-716. doi:10.1093/bjd/ljae491
Program Prior Authorization/Medical Necessity – Spevigo® (spesolimab-sbzo)
Change Control
5/2024 New program.
5/2025 Annual review. Revised diagnostic criteria per consensus guidelines.
Updated combination use language. Updated references.
© 2025 UnitedHealthcare Services, Inc.
3